These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35235473)

  • 1. Emerging drugs for the treatment of cutaneous T-cell lymphoma.
    Cheng M; Zain J; Rosen ST; Querfeld C
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):45-54. PubMed ID: 35235473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 4. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
    Afifi S; Mohamed S; Zhao J; Foss F
    Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
    [No Abstract]   [Full Text] [Related]  

  • 7. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
    Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
    FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
    Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
    J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental treatment strategies in primary cutaneous T-cell lymphomas.
    Rozati S; Kim YH
    Curr Opin Oncol; 2016 Mar; 28(2):166-71. PubMed ID: 26844985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment strategies and emerging therapies for cutaneous lymphoma.
    Yonekura K
    J Dermatol; 2022 Feb; 49(2):223-231. PubMed ID: 34958516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapies targeting cutaneous T cell lymphomas and their microenvironment.
    Reneau JC; Wilcox RA
    Semin Hematol; 2021 Apr; 58(2):103-113. PubMed ID: 33906720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?
    Guenova E; Hoetzenecker W; Rozati S; Levesque MP; Dummer R; Cozzio A
    Expert Opin Investig Drugs; 2014 Apr; 23(4):457-67. PubMed ID: 24397291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
    Xu S; Foss F
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
    de Masson A; Darbord D; Dobos G; Boisson M; Roelens M; Ram-Wolff C; Cassius C; Le Buanec H; de la Grange P; Jouenne F; Louveau B; Sadoux A; Bouaziz JD; Marie-Cardine A; Bagot M; Moins-Teisserenc H; Mourah S; Battistella M
    Blood; 2022 Mar; 139(12):1820-1832. PubMed ID: 34905599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New biotherapies for the treatment of cutaneous T-cell lymphomas.
    de Masson A
    Presse Med; 2022 Mar; 51(1):104110. PubMed ID: 35026391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic approaches for cutaneous T cell lymphomas.
    Pavlidis A; Piperi C; Papadavid E
    Expert Rev Clin Immunol; 2021 Jun; 17(6):629-641. PubMed ID: 33890833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.